

Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis

Fen Qin^{1,*}
Quan Wang^{2,*}
Chunlian Zhang¹
Caiyun Fang¹
Liping Zhang¹
Hailin Chen¹
Mi Zhang³
Fei Cheng³

¹Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China; ²Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China; ³Department of Cardiology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China

*These authors contributed equally to this work

Purpose: Antifungal drugs are used frequently in the treatment of vulvovaginal candidiasis (VVC), but have shown controversial results. In this study, we aimed to evaluate the effectiveness of different antifungal drugs in the treatment of VVC and to provide an evidence-based reference for clinical use.

Methods: The published studies on the effectiveness of antifungal drugs in the treatment of VVC (up to April 2018) were retrieved from PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. We sifted through the literature according to Patients, Interventions, Comparisons and Outcomes principle, extracted data on the basic characteristics of the study, and evaluated the quality of included studies. We used R software for statistical analysis.

Results: In total, 41 randomized controlled trials were included in this meta-analysis. The relative risk of VVC associated with ten drugs, including placebo, fluconazole, clotrimazole, miconazole, itraconazole, ketoconazole, econazole, butoconazole, terbinafine, and terconazole, was analyzed. The following drugs appeared to show more efficacy than placebo in the treated patients: fluconazole (OR =6.45, 95% CrI 4.42–9.41), clotrimazole (OR =2.99, 95% CrI 1.61–5.55), miconazole (OR =5.96, 95% CrI 3.17–11.2), itraconazole (OR =2.29, 95% CrI 1.21–4.33), ketoconazole (OR =2.40, 95% CrI 1.55–3.71), butoconazole (OR =1.18, 95% CrI 1.06–1.31), and terconazole (OR =5.60, 95% CrI 2.78–11.3). The value of surface under the cumulative ranking curve of each drug was as follows: placebo (0.5%), fluconazole (91.5%), clotrimazole (61.8%), miconazole (33.8%), itraconazole (50.5%), ketoconazole (42.8%), econazole (46.8%), butoconazole (82.2%), terbinafine (20.9%), and terconazole (65.0%).

Conclusion: Antifungal drugs are effective in the treatment of VVC. Fluconazole appeared to be the best drug for the treatment of VVC according to our analysis.

Keywords: vulvovaginal candidiasis, antifungal drugs, randomized controlled trials, network meta-analysis

Introduction

Vulvovaginal candidiasis (VVC) is an infectious disease affecting the female genital tract and is caused by *Candida* spp. Of all the VCC cases, 80%–90% are caused by *Candida albicans*, and a minority are caused by *Candida glabrata*, *Candida parapsilosis*, and *Candida tropicalis*.¹ As one of the most common infectious diseases of the female genital tract, VVC is found worldwide affecting the health of women at all levels of the society.² With the widespread use of corticosteroids, broad-spectrum antibiotics, and immunosuppressants, as well as the emergence of AIDS, VVC is more commonly encountered in clinical practice,^{3,4} and the treatment of VVC has become a hot issue.

Correspondence: Fei Cheng
Department of Cardiology, Taihe
Hospital, Hubei University of Medicine,
32 Renmin Nan Road, Shiyan, Hubei,
China
Email fei__cheng@sina.com

Antifungal drugs exert their effect by changing the permeability of fungal cell membrane. At present, two groups of antifungal drugs are mainly used to treat VVC: polyene antifungal drugs and pyrrole ring antifungal drugs. The former group is represented by amphotericin B. Amphotericin B has a strong antifungal activity and a wide antibacterial spectrum, but it is quite toxic. The latter group includes azoles, such as ketoconazole, fluconazole, and itraconazole. These are also most widely used and have a wide antibacterial spectrum.^{5,6}

To evaluate the clinical efficacy of different antifungal drugs in the treatment of VVC and to provide an evidence-based reference for clinical use, we conducted a network meta-analysis based on randomized controlled trials on the efficacy of antifungal drugs in the treatment of VVC.

Methods

Search strategy

The published studies on the effectiveness of antifungal drugs in the treatment of oral candidiasis (up to April 2018) were retrieved from PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov, with keywords including “Vulvovaginal Candidiasis” [MeSH] OR “Vulvovaginal Candidiasis” [MeSH] OR “Vulvovaginal Moniliasis” [MeSH] OR “Vulvovaginal Moniliasis” [MeSH] OR “Vaginal Yeast Infections” [MeSH] OR “Genital Vulvovaginal Candidiasis” [MeSH] OR “Genital Vulvovaginal Candidiasis” [MeSH] OR “Genital Candidiasis” [MeSH] OR “Genital Candidiasis” [MeSH] OR “Monilial Vaginitides” [MeSH] OR “Monilial Vaginitis” [MeSH] AND “Antifungal Agents” [MeSH] OR “Itraconazole” [MeSH] OR “Miconazole” [MeSH] OR “Clotrimazole” [MeSH] OR “Fluconazole” [MeSH] OR “Ketoconazole” [MeSH] OR “Econazole” [MeSH] OR “Butoconazole” [MeSH] OR “Terbinafine” [MeSH] OR “Terconazole” [MeSH] AND “Randomized Controlled Trials” [MeSH] OR “RCT” [MeSH].

Inclusion and exclusion criteria

We included randomized controlled trials written in English, regardless of whether or not specific random allocation methods and blind data hiding scheme are mentioned and the timing of publication. Study subjects were females with typical clinical symptoms and signs of VVC confirmed by mycological examination.

We imported the literature retrieved from the database into EndNote and eliminated duplicates. We screened the titles and abstracts according to the Patients, Interventions, Comparisons and Outcomes principle, and then read the full text of the eligible articles. The data were extracted and

evaluated by two reviewers. Any differences in opinion were discussed and resolved by the reviewers. The following data were extracted: first author of the study, publication time, sample size, age, and intervention measures. Quality evaluation was performed using Cochrane risk-of-bias assessment tool.

Statistical analysis

We conducted a network meta-analysis (Bayesian approach) which included both direct and indirect evidence in the network. Direct comparison was performed using Stata14.0 software for statistical analysis. The risk of vulvovaginal candidiasis in each group was compared using the OR. Before the combined data were analyzed by meta-analysis, the heterogeneity of each group was tested. If there was no heterogeneity ($P \geq 0.05$ or $I^2 \leq 50\%$), the combined statistics were calculated by fixed-effect model analysis. If there was significant heterogeneity among the groups ($P < 0.05$ or $I^2 > 50\%$), the source of heterogeneity was analyzed, and a subgroup analysis of the factors leading to heterogeneity was carried out. Indirect comparison was made using R software to draw a mesh diagram. Drugs were ranked based on the surface under the cumulative ranking curve (SUCRA) values. A drug was considered more preferable than another if it had a larger SUCRA value.

Results

Literature search results

A total of 566 studies from Medline, 596 studies from Embase, one study from Cochrane Library, and eight studies from ClinicalTrials.gov were selected. After removing duplicates, 581 studies remained. After reviewing their titles and abstracts, 521 citations were excluded. The remaining 60 citations were assessed in more detail for eligibility by reading the full text. Among them, two were excluded due to lack of relevant outcome measure, 14 were excluded due to insufficient network connections, and three were excluded due to lack of detailed information. Finally, 41 studies were used for the final data synthesis.^{5,7-46} The flowchart of literature search is presented in Figure 1. The risk of bias of the 41 studies included in this meta-analysis is summarized in Figure 2. The characteristics of the included studies are shown in Table 1. The pattern of evidence within the network is displayed in Figure 3.

Results of pairwise meta-analysis

Table 2 displays the results produced by pairwise meta-analysis. The following drugs appeared to show more efficacy than placebo in the treated patients: fluconazole (OR =6.45, 95% CrI 4.42–9.41), clotrimazole (OR =2.99, 95%




Figure 1 Flow diagram of the study selection process.

CrI 1.61–5.55), miconazole (OR =5.96, 95% CrI 3.17–11.2), itraconazole (OR =2.29, 95% CrI 1.21–4.33), ketoconazole (OR =2.40, 95% CrI 1.55–3.71), butoconazole (OR =1.18, 95% CrI 1.06–1.31), and terconazole (OR =5.60, 95% CrI 2.78–11.3). Moreover, there was no significant heterogeneity among the studies for the above results (P -heterogeneity >0.05 and I^2 <50%).

Network meta-analysis

Table 3 displays the results produced by network meta-analysis. The following nine drugs appeared to show more efficacy than placebo in the treated patients: fluconazole (OR =26.0, 95% CrI 14.0–50.0), clotrimazole (OR =17.0, 95% CrI 8.70–34.0), miconazole (OR =12.0, 95% CrI 6.30–22.0), itraconazole (OR =14.0, 95% CrI 6.40–32.0), ketoconazole (OR =13.0, 95% CrI 6.10–27.0), econazole (OR =14.0, 95% CrI 5.10–38.0), butoconazole (OR =25.0, 95% CrI 12.0–56.0), terbinafine (OR =5.20, 95% CrI 1.70–35.0), and terconazole (OR =18.0, 95% CrI 7.80–43.0).

The corresponding SUCRA values of the drugs were as follows: placebo (0.5%), fluconazole (91.5%), clotrimazole (61.8%), miconazole (33.8%), itraconazole (50.5%), ketoconazole (42.8%), econazole (46.8%), butoconazole (82.2%), terbinafine (20.9%), and terconazole (65.0%) (Figure 4). Incorporating adjuvants particularly fluconazole appeared to be the best strategy for the treatment of oral candidiasis.

Publication bias

The results of the comparison-adjusted funnel plots did not reveal any evidence of apparent asymmetry (Figure 5). No significant publication bias was observed.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Adamson 1986	?	?	+	?	?	?	+
Andersen 1989	+	?	+	?	?	+	?
Brown 1986	?	?	?	?	?	?	?
Brown 1999	+	+	?	?	?	?	?
Corić 2006	+	+	+	?	?	+	+
Corson 1991	?	+	?	+	?	+	+
Costa 2004	+	+	+	+	?	?	+
De Punzio 2003	+	+	+	+	?	+	?
Fan 2015	?	+	+	+	+	+	+
Ferahbas 2006	+	?	?	?	?	+	+
Fong 1992	?	?	?	?	?	+	+
Gerhard 1989	+	?	?	+	?	+	+
Hajman 1988	+	?	?	+	+	?	?
Kaufman 1989	?	?	?	+	+	+	?
Kjaeldgaard 1986	?	?	?	+	+	+	+
Kutzer 1988	+	+	?	?	?	?	?
Li 2015	+	+	+	?	?	+	+
McClelland 2015	+	+	+	+	?	+	+
Mendling 2004	+	+	+	+	+	+	+
Mikamo 1995	?	?	+	?	+	?	?
Mikamo 1998	+	+	?	?	?	+	?
O-Prasertsawat 1995	?	?	?	?	+	+	+
Osser 1991	?	?	?	?	?	+	?
Perera 1994	+	?	?	?	?	?	?
Puolakka 1983	?	?	?	?	?	?	?
Ruf 1990	+	+	?	?	?	?	+
Seidman 2005	+	+	?	?	+	+	+
Sekhavat 2011	+	+	+	+	+	+	+
Sobel 1986	+	+	+	?	?	?	+
Sobel 1994	?	?	?	+	+	?	+
Sobel 1995	?	?	?	?	?	?	+
Sobel 2004	+	+	+	?	?	+	+
Stein 1993	?	?	?	?	?	?	?
Stein 2001	?	?	+	+	?	+	+
Stettendorf 1982	?	?	?	?	+	+	+
Thomason 1990	+	?	?	+	?	+	?
Timonen 1992	+	?	?	+	?	?	+
Tobin 1992	?	?	?	?	?	?	?
van der Meijden 1986	?	?	?	+	+	?	?
van Heusden 1990	?	?	?	+	+	?	?
Zhou 2016	+	+	+	+	+	+	+

Figure 2 Risk of bias of the included randomized controlled trials (review authors' judgments about each risk-of-bias item for each included study). Note: +, low risk; -, high risk; ?, unclear risk.

Table 1 Characteristics of the included studies

Study	Year	Study location	Treatments			Cases/n			Treatment 2	Age (years)	Cases/n	Treatment 3	Age (years)	Cases/n
			Treatment 1	Age (years)	Cases/n	Treatment 2	Age (years)	Cases/n						
Andersen et al ⁷	1989	France	Fluconazole	32.1	143/169	Clotrimazole	30.6	131/161						
Corić et al ⁸	2006	Croatia	Fluconazole	NA	41/56	Clotrimazole	NA	9/13						
Costa et al ⁹	2004	Brazil	Fluconazole	NA	30/38	Itraconazole	NA	27/42						
de Punzio et al ¹⁰	2003	Italy	Fluconazole	>18.0	29/38	Itraconazole	>18.0	21/32						
Fan et al ¹¹	2015	China	Fluconazole	19.0–45.0	241/287	Miconazole	19.0–45.0	220/290						
Ferahbas et al ¹²	2006	Turkey	Fluconazole	17.0–54.0	10/15	Itraconazole	17.0–54.0	6/10						4/12
Li et al ¹³	2015	China	Fluconazole	29.6	46/58	Terconazole	31.0	47/66						
McClelland et al ¹⁴	2015	USA	Miconazole	24.0–34.0	75/118	Placebo	23.0–35.0	30/116						
Mending et al ¹⁵	2004	Germany	Fluconazole	NA	129/161	Clotrimazole	NA	117/154						
Mikamo et al ¹⁶	1995	Japan	Fluconazole	18.0–54.0	38/50	Clotrimazole	18.0–54.0	30/50						
Mikamo et al ¹⁵	1998	Japan	Fluconazole	18.0–55.0	40/50	Itraconazole	17.0–55.0	42/50						36/50
O-Prasertsawat and Bourlert ¹⁷	1995	China	Fluconazole	33.9±8.1	42/53	Clotrimazole	35.3±8.4	40/50						
Osser et al ¹⁸	1991	Sweden	Fluconazole	16.0–52.0	100/121	Econazole	18.0–60.0	84/114						
Seidman and Skokos ¹⁹	2005	USA	Fluconazole	37.0±12.2	76/93	Butoconazole	38.8±13.8	56/88						
Sekhavat et al ²⁰	2011	Iran	Fluconazole	39.4±13.1	60/72	Clotrimazole	42.2±15.9	49/70						
Sobel et al ²¹	1995	USA	Fluconazole	18.0–63.0	133/182	Clotrimazole	17.0–64.0	118/176						
Sobel et al ²²	2004	USA	Fluconazole	NA	160/166	Placebo	NA	23/154						
Stein et al ²³	1991	USA	Fluconazole	18.0–51.0	80/90	Clotrimazole	18.0–60.0	88/95						
Stein and Mummaw ²⁴	1993	USA	Itraconazole	18.0–43.0	35/48	Clotrimazole	18.0–33.0	19/20						7/22
Timonen ²⁵	1992	Finland	Fluconazole	>18.0	50/54	Miconazole	>18.0	33/47						
Tobin et al ²⁶	1992	UK	Itraconazole	>18.0	60/92	Clotrimazole	>18.0	49/88						
van Heusden et al ²⁷	1990	Netherlands	Fluconazole	NA	47/49	Miconazole	NA	48/50						
Zhou et al ²⁸	2016	China	Fluconazole	29.9±6.5	61/110	Clotrimazole	29.4±6.2	62/115						
Sobel et al ⁴²	1994	USA	Ketoconazole	>18.0	86/101	Clotrimazole	>18.0	41/51						
Fong ²⁹	1992	Canada	Itraconazole	18.0–65.0	17/22	Clotrimazole	18.0–65.0	21/22						
Gerhard et al ⁴³	1989	USA	Ketoconazole	>18.0	27/45	Placebo	>18.0	21/47						
Kutzer et al ⁴⁶	1988	UK	Fluconazole	17.0–65.0	63/80	Ketoconazole	17.0–72.0	55/72						
Sobel ⁴⁴	1986	USA	Ketoconazole	31.9	15/21	Placebo	31.9	6/21						
van der Meijden et al ⁴⁵	1986	Netherlands	Ketoconazole	29.0±6.9	20/23	Miconazole	28.0±7.4	18/19						
Kjaeldgaard ⁵⁸	1986	USA	Terconazole	>18.0	18/20	Clotrimazole	>18.0	17/20						
Puolikka and Tuimala ³⁰	1983	Finland	Ketoconazole	16.0–46.0	40/49	Miconazole	18.0–47.0	34/49						
Corson et al ³¹	1991	USA	Terconazole	18.0–54.0	250/299	Miconazole	18.0–54.0	239/294						
Thomason et al ³²	1990	USA	Terconazole	NA	40/50	Miconazole	NA	34/50						7/49
Brown et al ³⁹	1999	USA	Butoconazole	18.0–65.0	93/101	Miconazole	18.0–65.0	90/104						
Ruf and Vitse ⁴⁰	1990	France	Butoconazole	18.0–56.0	26/29	Econazole	16.0–49.0	24/32						
Kaufman et al ³⁷	1989	USA	Butoconazole	>18.0	101/115	Miconazole	>18.0	93/114						
Hajman ³⁸	1988	Sweden	Butoconazole	20.0–63.0	28/32	Clotrimazole	19.0–32.0	24/31						2/29
Brown et al ³³	1986	USA	Butoconazole	>18.0	26/32	Miconazole	>18.0	21/30						
Adamson et al ³⁴	1986	USA	Butoconazole	NA	92/97	Clotrimazole	NA	74/88						
Stettendorf et al ³⁵	1982	USA	Clotrimazole	16.0–62.0	45/54	Econazole	16.0–66.0	41/57						
Perera and Seneviratne ³⁶	1994	Sri Lanka	Econazole	NA	49/51	Clotrimazole	NA	45/50						

Discussion

VVC has a high incidence and recurrence rate, but its pathogenesis is not yet clear.⁴⁷ At present, it is believed that the pathogenesis and recurrence of VVC are related to many factors, such as the increasing resistance of *Candida*, the local immune response of host against *Candida*, and the change




Figure 3 Network of randomized controlled trials comparing different antifungal drugs for vulvovaginal candidiasis treatment.

Note: The thickness of the connecting lines represents the number of trials between each comparator, and the size of each node corresponds to the number of subjects who received the same pharmacological agent (sample size) (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).

of virulence factor of *Candida*.^{48,49} Available data show that 75% of women have VVC at least once in their lifetime, and 50% of women with VVC have recurrent infections, with the highest incidence found among women of reproductive age.⁵⁰ VVC is the most common cause of vaginal infections, second only to bacterial vaginitis. *Candida* has a high rate of intravaginal colonization; it can be isolated from the vagina of about 20% of healthy asymptomatic women and 30% of pregnant women.⁵¹

Candida, as a part of normal flora, can be found on the surface of the skin, digestive tract, and genitourinary tract; however, the mechanism of colonization and pathogenicity of *Candida* are unclear. The pathogens of VVC include *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *Candida krusei*, and *C. glabrata*.⁵² *C. albicans* is the main pathogen of VVC, and accounts for 73.8%–95.0% of all *Candida* spp. isolated from the vagina. The most common non-albicans species is *C. glabrata*, which accounts for 10%–20% of all VVC pathogens.⁵³ VVC causes increased leucorrhea, vulva itching, burning pain, urinal pain, and intercourse pain, and seriously affects the physical and mental health of the majority of women. Therefore, there is an urgent need for most suitable drugs for the treatment of VVC.

Table 2 Summary ORs of antifungal drugs and heterogeneity of each direct comparison

Comparison	OR (95% CI)	P-heterogeneity	I ²	Tau ²
Fluconazole vs placebo	6.45 (4.42, 9.41)	–	–	<0.001
Clotrimazole vs placebo	2.99 (1.61, 5.55)	–	–	0.001
Miconazole vs placebo	5.96 (3.17, 11.2)	0.323	0.0%	<0.001
Itraconazole vs placebo	2.29 (1.21, 4.33)	–	–	0.011
Ketoconazole vs placebo	2.40 (1.55, 3.71)	0.894	0.0%	<0.001
Butoconazole vs placebo	1.18 (1.06, 1.31)	–	–	<0.001
Terconazole vs placebo	5.60 (2.78, 11.3)	–	–	<0.001
Clotrimazole vs fluconazole	0.94 (0.89, 0.99)	0.387	5.7%	0.016
Miconazole vs fluconazole	0.90 (0.84, 0.96)	0.108	46.7%	0.001
Itraconazole vs fluconazole	0.92 (0.80, 1.06)	0.408	0.0%	0.245
Ketoconazole vs fluconazole	0.97 (0.82, 1.15)	–	–	0.728
Econazole vs fluconazole	0.89 (0.77, 1.02)	–	–	0.100
Butoconazole vs fluconazole	0.78 (0.65, 0.94)	–	–	0.008
Terbinafine vs fluconazole	0.50 (0.21, 1.20)	–	–	0.121
Terconazole vs fluconazole	0.89 (0.73, 1.10)	–	–	0.296
Itraconazole vs clotrimazole	0.96 (0.75, 1.23)	0.002	47.1%	0.738
Ketoconazole vs clotrimazole	1.05 (0.90, 1.24)	–	–	0.476
Econazole vs clotrimazole	0.97 (0.76, 1.24)	0.032	38.4%	0.821
Butoconazole vs clotrimazole	1.13 (1.03, 1.24)	0.987	0.0%	0.013
Terconazole vs clotrimazole	1.06 (0.83, 1.34)	–	–	0.634
Ketoconazole vs miconazole	1.08 (0.92, 1.27)	0.066	44.7%	0.349
Butoconazole vs miconazole	1.08 (1.01, 1.16)	0.844	0.0%	0.037
Terconazole vs miconazole	1.04 (0.98, 1.12)	0.281	13.9%	0.210
Terbinafine vs itraconazole	0.56 (0.22, 1.43)	–	–	0.224
Butoconazole vs econazole	1.19 (0.95, 1.51)	–	–	0.137

Table 3 Network meta-analysis comparisons

	Placebo	Fluconazole	Clotrimazole	Miconazole	Itraconazole	Ketoconazole	Econazole	Butoconazole	Terbinafine	Terconazole
Placebo	I	0.04 (0.02, 0.07)	0.06 (0.03, 0.12)	0.09 (0.05, 0.16)	0.07 (0.03, 0.15)	0.08 (0.04, 0.16)	0.07 (0.03, 0.19)	0.04 (0.02, 0.09)	0.19 (0.03, 0.58)	0.06 (0.02, 0.13)
Fluconazole	26.0 (14.0, 50.0)	I	1.50 (1.1, 2.20)	2.20 (1.30, 3.90)	1.80 (0.99, 3.30)	2.00 (1.00, 4.10)	1.90 (0.84, 4.20)	1.00 (0.54, 1.90)	4.90 (0.85, 32.0)	1.40 (0.65, 3.10)
Clotrimazole	17.0 (8.70, 34.0)	0.66 (0.45, 0.95)	I	1.50 (0.80, 2.70)	1.20 (0.65, 2.20)	1.30 (0.64, 2.80)	1.20 (0.56, 2.70)	0.68 (0.35, 1.30)	3.30 (0.55, 22.0)	0.95 (0.41, 2.10)
Miconazole	12.0 (6.30, 22.0)	0.45 (0.26, 0.78)	0.68 (0.37, 1.20)	I	0.79 (0.38, 1.80)	0.90 (0.44, 1.90)	0.84 (0.33, 2.10)	0.47 (0.24, 0.87)	2.20 (0.36, 15.0)	0.65 (0.31, 1.30)
Itraconazole	14.0 (6.40, 32.0)	0.56 (0.30, 1.00)	0.85 (0.46, 1.50)	1.30 (0.57, 2.70)	I	1.10 (0.47, 2.70)	1.10 (0.39, 2.70)	0.58 (0.24, 1.30)	2.80 (0.48, 18.0)	0.81 (0.30, 2.10)
Ketoconazole	13.0 (6.10, 27.0)	0.50 (0.24, 1.00)	0.76 (0.36, 1.60)	1.10 (0.53, 2.30)	0.88 (0.37, 2.20)	I	0.94 (0.33, 2.60)	0.52 (0.21, 1.20)	2.50 (0.38, 18.0)	0.72 (0.27, 1.80)
Econazole	14.0 (5.10, 38.0)	0.53 (0.24, 1.20)	0.80 (0.36, 1.80)	1.20 (0.47, 3.00)	0.94 (0.37, 2.50)	1.10 (0.38, 3.00)	I	0.55 (0.22, 1.40)	2.60 (0.38, 20.0)	0.77 (0.26, 2.20)
Buroconazole	25.0 (12.0, 56.0)	0.96 (0.51, 1.80)	1.50 (0.77, 2.80)	2.10 (1.10, 4.10)	1.70 (0.76, 4.40)	1.90 (0.83, 4.70)	1.80 (0.73, 4.60)	I	4.70 (0.74, 34.0)	1.40 (0.57, 3.40)
Terbinafine	5.20 (1.70, 35.0)	0.20 (0.03, 1.20)	0.31 (0.05, 1.80)	0.45 (0.06, 2.80)	0.35 (0.05, 2.10)	0.40 (0.06, 2.70)	0.38 (0.05, 2.60)	0.21 (0.03, 1.30)	I	0.29 (0.04, 2.00)
Terconazole	18.0 (7.80, 43.0)	0.69 (0.32, 1.50)	1.10 (0.47, 2.40)	1.50 (0.75, 3.20)	1.20 (0.49, 3.30)	1.40 (0.55, 3.70)	1.30 (0.45, 3.90)	0.72 (0.29, 1.80)	3.40 (0.51, 26.0)	I




Figure 4 Surface under the cumulative ranking curve (SUCRA), expressed as percentages, ranking the therapeutic effects and safety of treatments for vulvovaginal candidiasis.

Note: For efficacy and safety assessment, the pharmacological agent with the highest SUCRA value would be the most efficacious and safe treatment (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).

At present, pyrrole ring drugs are mainly used to treat VVC in clinical practice. Pyrrole ring drugs such as imidazoles and triazoles are related to the inhibition of ergosterol synthesis in fungi and thus destroy the integrity of fungal cell membrane and achieve the antifungal effect.⁵⁴ The most common drugs represented by imidazoles are clotrimazole, ketoconazole, and miconazole. Triazoles are represented by fluconazole and itraconazole. Triazole antifungal drugs have a high bioavailability and strong antifungal effect, and the associated liver toxicity is relatively small.⁵⁵

This network meta-analysis attempted to analyze the effectiveness of different antifungal drugs in the treatment of VVC and to provide an evidence-based reference for clinical use. Our analysis suggested that antifungal drugs are effective in the treatment of VVC, and fluconazole appeared to be best drug for the treatment of VVC. The American and European guidelines for the treatment of VVC, based on a large number of evidence-based clinical practice, recommended the use of fluconazole (150 mg) for the treatment of moderate-to-severe VVC, which is consistent with our results.

Fluconazole is a triazole antifungal drug that can inhibit or kill fungi by competitively inhibiting the synthesis of ergosterol. It has shown a significant effect in the treatment of deep fungal infections, especially those caused by *C. albicans* and *Cryptococcus neoformans*.⁵⁶ Since it was launched in 1988, fluconazole has been widely used in clinical practice because of its excellent pharmacokinetic properties, such as broad antifungal spectrum, low hepatotoxicity, good oral absorption, high bioavailability, and wide tissue distribution.⁵⁷ Designated by the WHO as the first choice for the treatment of systemic fungal infections, fluconazole is effective




Figure 5 Comparison-adjusted funnel plot for the network meta-analysis.

Notes: The red line suggests the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. Different colors represent different comparisons (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).

for various human and animal fungal infections, such as *Candida* infection (including systemic candidiasis in normal or immune-impaired people and animals), new cryptococcus infection (including intracranial infection), *Malassezia*, *Microsporum*, and *Trichophyton* infections, psoriasis, dermatitis, and rougherisporum (including intracranial infection). The antibacterial activity of fluconazole in vitro was found to be significantly lower than that of ketoconazole, but the antifungal activity of this drug was significantly higher than ketoconazole in vitro.⁵⁷

This meta-analysis also has some limitations. The results of statistical heterogeneity analysis of the antifungal drugs are limited in randomized controlled trials. In addition, the limited evidence of a dose-dependent association between antifungal drugs and VVC treatment provides limited confidence in the study findings. Second, there is no record for a standardized treatment of VVC, which leads to difference in results between the trials; therefore, these results should be carefully interpreted with caution. Third, the study durations were short in these randomized controlled trials and patients included in these trials might be different from patients in the real life. Fourth, these findings may not be generalizable to a specific group of patients because randomized controlled

trials tended to exclude participants. Fifth, most of the including studies have not enough detail in their reports, such as the absence of a random allocation method, the implementation of the allocation concealment, or the implementation of the blind law, which leads to existence of varying degrees of bias and risk.

Our findings underscore the notion that antifungal drugs are effective in the treatment of VVC, and fluconazole appeared to be the best drug for the treatment of VC according to our analysis. However, due to the low quality of the included studies, this conclusion needs to be further confirmed by high-quality research with a large sample.

Author contributions

Fei Cheng was responsible for the concept and design of the review, the acquisition of data, the analysis and interpretation of data, and for the preparation of the manuscript. Fen Qin was responsible for the acquisition of data and for the preparation of the manuscript. Quan Wang was responsible for the analysis and interpretation of data and for the preparation of the manuscript. Chunlian Zhang and Caiyun Fang was responsible for the acquisition of data. Liping Zhang and Hailin Chen was responsible for the analysis

and interpretation of data and for the preparation of the manuscript. Mi Zhang was responsible for the preparation of the manuscript. All authors read and approved the final version of the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Martin Lopez JE. Candidiasis (vulvovaginal). *BMJ Clin Evid*. 2015;16.
- Nwadioha SI, Nwokedi EO, Egesie J, Enejuo H. Vaginal candidiasis and its risk factors among women attending a Nigerian teaching hospital. *Niger Postgrad Med J*. 2013;20(1):20–23.
- Rathod SD, Buffler PA. Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. *BMC Womens Health*. 2014;14(1):1472–6874.
- Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. *Crit Rev Microbiol*. 2016;42(6):905–927.
- Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. *Chemotherapy*. 1998;44(5):364–368.
- Dovnik A, Golle A, Novak D, Arko D, Takač I. Treatment of vulvovaginal candidiasis: a review of the literature. *Acta Dermatovenerol Alp Pannonica Adriat*. 2015;24(1):5–7.
- A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Report of an international multicenter trial. *Br J Obstet Gynaecol*. 1989;96(2):226–232.
- Corić M, Barisić D, Lovrić H. Fluconazole versus 3-day clotrimazole in the treatment of sporadic and recurrent vulvovaginal candidiasis. *Int J Gynaecol Obstet*. 2006;95(2):171–172.
- Costa M, Passos XS, Miranda AT, de Araújo RS, Paula CR, Silva MR. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. *Mycopathologia*. 2004;157(1):43–47.
- de Punzio C, Garutti P, Mollica G, Nappi C, Piccoli R, Genazzani AR. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. *Eur J Obstet Gynecol Reprod Biol*. 2003;106(2):193–197.
- Fan S, Liu X, Liang Y. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. *Gynecol Obstet Invest*. 2015;80(2):113–118.
- Ferahbas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of Vulvovaginal candidiasis. *Am J Ther*. 2006;13(4):332–336.
- Li T, Zhu Y, Fan S, Liu X, Xu H, Liang Y. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. *Med Mycol*. 2015;53(5):455–461.
- McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. *J Infect Dis*. 2015;211(12):1875–1882.
- Mendling W, Krauss C, Fladung B. A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. *Mycoses*. 2004;47(3-4):136–142.
- Mikamo H, Izumi K, Ito K, Tamaya T. Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis. *Infect Dis Obstet Gynecol*. 1995;3(1):7–11.
- O-Prasertsawat P, Bourlert A. Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. *Sex Transm Dis*. 1995;22(4):228–230.
- Osser S, Haglund A, Weström L. Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. *Acta Obstet Gynecol Scand*. 1991;70(1):73–78.
- Seidman LS, Skokos CK. An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. *Infect Dis Obstet Gynecol*. 2005;13(4):197–206.
- Sekhavat L, Tabatabaai A, Tezerjani FZ. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. *J Infect Public Health*. 2011;4(4):195–199.
- Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of *Candida vaginitis*. Fluconazole Vaginitis Study Group. *Am J Obstet Gynecol*. 1995;172(4 Pt 1):1263–1268.
- Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med*. 2004;351(9):876–883.
- Stein GE, Christensen S, Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. *DIAP*. 1991;25(6):582–585.
- Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. *Antimicrob Agents Chemother*. 1993;37(1):89–92.
- Timonen H. Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. *Mycoses*. 1992;35(11-12):317–320.
- Tobin JM, Loo P, Granger SE. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. *Genitourin Med*. 1992;68(1):36–38.
- van Heusden AM, Merkus HM, Corbeij RS, et al. Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. *Acta Obstet Gynecol Scand*. 1990;69(5):417–422.
- Zhou X, Li T, Fan S, et al. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. *Mycoses*. 2016;59(7):419–428.
- Fong IW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. *Genitourin Med*. 1992;68(6):374–377.
- Puolakka J, Tuimala R. Comparison between oral ketoconazole and topical miconazole in the treatment of vaginal candidiasis. *Acta Obstet Gynecol Scand*. 1983;62(6):575–577.
- Corson SL, Kapikian RR, Nehring R. Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison. *J Reprod Med*. 1991;36(8):561–567.
- Thomason JL, Gelbart SM, Kellett AV, Scaglione NJ, Gotwalt KT, Broekhuizen FF. Terconazole for the treatment of vulvovaginal candidiasis. *J Reprod Med*. 1990;35(11):992–994.
- Brown D, Henzl MR, Lepage ME, et al. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis. Comparison with miconazole nitrate and placebo. *J Reprod Med*. 1986;31(11):1045–1048.
- Adamson GD, Brown D, Standard JV, Henzl MR. Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis. *J Reprod Med*. 1986;31(2):131–132.
- Stettendorf S, Benijts G, Vignali M, Kreysing W. Three-day therapy of vaginal candidiasis with clotrimazole vaginal tablets and econazole ovules: a multicenter comparative study. *Chemotherapy*. 1982;28 Suppl 1:87–91.
- Perera J, Seneviratne HR. Econazole and clotrimazole in the treatment of vaginal candidiasis: a double blind comparative study. *Ceylon Med J*. 1994;39(3):132–134.
- Kaufman RH, Henzl MR, Brown D, et al. Comparison of three-day butoconazole treatment with seven-day miconazole treatment for vulvovaginal candidiasis. *J Reprod Med*. 1989;34(7):479–483.

38. Hajman AJ. Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. *J Int Med Res.* 1988;16(5):367–375.
39. Brown D, Henzl MR, Kaufman RH. Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group. *J Reprod Med.* 1999;44(11):933–938.
40. Ruf H, Vitse M. A comparison of butoconazole nitrate cream with econazole nitrate cream for the treatment of vulvovaginal candidiasis. *J Int Med Res.* 1990;18(5):389–399.
41. Rohde-Werner H. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. *J Int Med Res.* 1984;12(5):298–302.
42. Sobel JD, Schmitt C, Stein G, Mummaw N, Christensen S, Meriwether C. Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. *J Reprod Med.* 1994;39(7):517–520.
43. Gerhard I, Ohlhorst D, Eggert-Kruse W, Runnebaum B. Topical one-time therapy with ketoconazole: a double-blind randomized study in vaginal mycosis. *Mycoses.* 1989;32(5):253–265.
44. Sobel JD. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. *N Engl J Med.* 1986;315(23):1455–1458.
45. van der Meijden WI, van der Hoek JC, Staal HJ, van Joost T, Stolz E. Double-blind comparison of 200-mg ketoconazole oral tablets and 1200-mg miconazole vaginal capsule in the treatment of vaginal candidosis. *Eur J Obstet Gynecol Reprod Biol.* 1986;22(3):133–138.
46. Kutzer E, Oittner R, Leodolter S, Brammer KW. A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial. *Eur J Obstet Gynecol Reprod Biol.* 1988;29(4):305–313.
47. Hong E, Dixit S, Fidel PL, Bradford J, Fischer G. Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition. *J Low Genit Tract Dis.* 2014;18(1):31–38.
48. Zhang JY, Liu JH, Liu FD, et al. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene over-expression. *Mycoses.* 2014;57(10):584–591.
49. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. *J Low Genit Tract Dis.* 2013;17(3):340–345.
50. Fardiazar Z, Ronaci F, Torab R, Goldust M. Vulvovaginitis candidiasis recurrence during pregnancy. *Pak J Biol Sci.* 2012;15(8):399–402.
51. Goldacre MJ, Watt B, Loudon N, Milne LJ, Loudon JD, Vessey MP. Vaginal microbial flora in normal young women. *Br Med J.* 1979;1(6176):1450–1455.
52. Guzel AB, Ilkit M, Akar T, Burgut R, Demir SC. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species. *Med Mycol.* 2011;49(1):16–25.
53. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep.* 2015;64(RR-03):1–137.
54. Lalla RV, Dongari-Bagtzoglou A. Antifungal medications or disinfectants for denture stomatitis. *Evid Based Dent.* 2014;15(2):61–62.
55. Peyton LR, Gallagher S, Hashemzadeh M. Triazole antifungals: a review. *Drugs Today.* 2015;51(12):705–718.
56. Eschenauer GA, Nguyen MH, Clancy CJ. Is fluconazole or an echinocandin the agent of choice for candidemia. *Ann Pharmacother.* 2015;49(9):1068–1074.
57. Wildfeuer A, Laufen H, Schmalreck AF, Yeates RA, Zimmermann T. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. *Mycoses.* 1997;40(7–8):259–265.
58. Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. *Pharmatherapeutica.* 1986;4(8):525–531.

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress